Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe. https://t.co/XYK02MRMp6 https://t.co/LgToS5NCaa